354 related articles for article (PubMed ID: 32227432)
1. Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
Verma S; Sharma A; Zinman B; Ofstad AP; Fitchett D; Brueckmann M; Wanner C; Zwiener I; George JT; Inzucchi SE; Butler J; Mazer CD
Diabetes Obes Metab; 2020 Jul; 22(7):1141-1150. PubMed ID: 32227432
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Fitchett D; Inzucchi SE; Cannon CP; McGuire DK; Scirica BM; Johansen OE; Sambevski S; Kaspers S; Pfarr E; George JT; Zinman B
Circulation; 2019 Mar; 139(11):1384-1395. PubMed ID: 30586757
[TBL] [Abstract][Full Text] [Related]
3. Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.
Verma S; Mazer CD; Inzucchi SE; Wanner C; Ofstad AP; Johansen OE; Zwiener I; George JT; Butler J; Zinman B
Diabetes Obes Metab; 2021 May; 23(5):1173-1181. PubMed ID: 33502090
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.
Inzucchi SE; Khunti K; Fitchett DH; Wanner C; Mattheus M; George JT; Ofstad AP; Zinman B
J Clin Endocrinol Metab; 2020 Sep; 105(9):3025-35. PubMed ID: 32485734
[TBL] [Abstract][Full Text] [Related]
5. Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial.
Verma S; Leiter LA; Zinman B; Sharma A; Mattheus M; Fitchett D; George J; Ofstad AP; Kosiborod MN; Wanner C; Inzucchi SE
ESC Heart Fail; 2021 Aug; 8(4):2603-2607. PubMed ID: 34132492
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
Monteiro P; Bergenstal RM; Toural E; Inzucchi SE; Zinman B; Hantel S; Kiš SG; Kaspers S; George JT; Fitchett D
Age Ageing; 2019 Nov; 48(6):859-866. PubMed ID: 31579904
[TBL] [Abstract][Full Text] [Related]
7. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
McGuire DK; Zinman B; Inzucchi SE; Wanner C; Fitchett D; Anker SD; Pocock S; Kaspers S; George JT; von Eynatten M; Johansen OE; Jamal W; Mattheus M; Elsasser U; Hantel S; Lund SS
Lancet Diabetes Endocrinol; 2020 Dec; 8(12):949-959. PubMed ID: 33217335
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
Levin A; Perkovic V; Wheeler DC; Hantel S; George JT; von Eynatten M; Koitka-Weber A; Wanner C;
Clin J Am Soc Nephrol; 2020 Oct; 15(10):1433-1444. PubMed ID: 32994159
[TBL] [Abstract][Full Text] [Related]
9. Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.
Fitchett D; Inzucchi SE; Wanner C; Mattheus M; George JT; Vedin O; Zinman B; Johansen OE
Eur Heart J; 2020 Jan; 41(2):209-217. PubMed ID: 31504427
[TBL] [Abstract][Full Text] [Related]
10. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.
Sharma A; Ofstad AP; Ahmad T; Zinman B; Zwiener I; Fitchett D; Wanner C; George JT; Hantel S; Desai N; Mentz RJ
JACC Heart Fail; 2021 Aug; 9(8):568-577. PubMed ID: 34325887
[TBL] [Abstract][Full Text] [Related]
11. The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.
Kaku K; Wanner C; Anker SD; Pocock S; Yasui A; Mattheus M; Lund SS
Diabetes Obes Metab; 2022 Apr; 24(4):662-674. PubMed ID: 34908223
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B
Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264
[TBL] [Abstract][Full Text] [Related]
13. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial.
Fitchett D; Inzucchi SE; Zinman B; Wanner C; Schumacher M; Schmoor C; Ohneberg K; Ofstad AP; Salsali A; George JT; Hantel S; Bluhmki E; Lachin JM; Zannad F
ESC Heart Fail; 2021 Dec; 8(6):4517-4527. PubMed ID: 34605192
[TBL] [Abstract][Full Text] [Related]
14. Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia.
Ji Q; Ji L; Mu Y; Zhao J; Zinman B; Wanner C; George JT; Zwiener I; Ueki K; Yokote K; Ogawa W; Johansen OE
Diabetes Obes Metab; 2021 Aug; 23(8):1886-1891. PubMed ID: 33950573
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
[TBL] [Abstract][Full Text] [Related]
16. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
[TBL] [Abstract][Full Text] [Related]
18. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
Fitchett D; Butler J; van de Borne P; Zinman B; Lachin JM; Wanner C; Woerle HJ; Hantel S; George JT; Johansen OE; Inzucchi SE;
Eur Heart J; 2018 Feb; 39(5):363-370. PubMed ID: 29020355
[TBL] [Abstract][Full Text] [Related]
19. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
